Article in Molecular cancer research : MCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors at 8 institutions in 4 countries.
Claire M StoreyDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0003-0792-1569
Mohamed AltaiDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0002-7624-0313
Mesude BicakHasso Plattner Institute for Digital Health, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-4546-9801
Darren R VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.ORCID 0000-0002-8201-622X
Katharina LückerathDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, DKTK, Essen, Germany.ORCID 0000-0001-6109-2066
Gabriel AdrianDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0001-8837-4696
Michael R McDevittDepartment of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.ORCID 0000-0002-8855-0917
Teja KalidindiDepartment of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.ORCID 0000-0002-0210-0270
Julie E ParkDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0002-3053-9969
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, DKTK, Essen, Germany.ORCID 0000-0002-9662-7259
Diane AbouDepartment of Radiology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-3005-9623
Wahed ZedanDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0002-0287-5367
Norbert PeekhausDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0001-9584-4879
Robert J KleinIcahn Institute for Genomics and Multiscale Biology, Department of Genetics and Genomic, Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0003-3539-5391
Robert DamoiseauxDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0002-7611-7534
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.ORCID 0000-0002-6111-7507
Hans LiljaGenitourinary Oncology Service, Department of Medicine, MSKCC, New York, New York.ORCID 0000-0001-5871-7846
Daniel ThorekDepartment of Radiology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-2437-1239
David UlmertDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, California.ORCID 0000-0002-7871-2281
Lund University · SEMemorial Sloan Kettering Cancer Center · USCalifornia NanoSystems Institute · USEssen University Hospital · DEIcahn School of Medicine at Mount Sinai · USUniversity of California, Los Angeles · USWashington University in St. Louis · USCommunity Service Society · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2000 to 2015
$29.9M
TREATMENT OF CANCER PATIENTS WITH THYMIC FACTORSP01CA033049 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HOUGHTON, ALAN N. · 1985 to 2009
$19.8M
RECOMBINANT ANTICD33 ANTIBODY FOR AMLR01CA055349 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1991 to 2020
$6.8M
Genetic Predictors of Prostate Cancer SurvivalR01CA244948 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT J. KLEIN · 2021 to 2026
$4.1M
The Radium-223 Combination Therapy Space; Improving Response and Clarifying ToxicitiesR01CA240711 · NCI · WASHINGTON UNIVERSITY · PI MICHALSKI, JEFF M., THOREK, DANIEL LYNDON JAFFE · 2020 to 2024
$2.2M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. AR is a critical driver and mediator of resistance of prostate cancer but currently available noninvasive prostate cancer biomarkers to monitor AR activity are discordant with downstream AR pathway activity. External beam radiotherapy (EBRT) remains a common treatment for all stages of prostate cancer, and DNA damage induced by EBRT upregulates AR pathway activity to promote therapeutic resistance. [89Zr]11B6-PET is a novel modality targeting prostate-specific protein human kallikrein 2 (hK2), which is a surrogate biomarker for AR activity. Here, we studied whether [89Zr]11B6-PET can accurately assess EBRT-induced AR activity.Genetic and human prostate cancer mouse models received EBRT (2-50 Gy) and treatment response was monitored by [89Zr]11B6-PET/CT. Radiotracer uptake and expression of AR and AR target genes was quantified in resected tissue.EBRT increased AR pathway activity and [89Zr]11B6 uptake in LNCaP-AR and 22RV1 tumors. EBRT increased prostate-specific [89Zr]11B6 uptake in prostate cancer-bearing mice (Hi-Myc x Pb_KLK2) with no significant changes in uptake in healthy (Pb_KLK2) mice, and this correlated with hK2 protein levels. IMPLICATIONS: hK2 expression in prostate cancer tissue is a proxy of EBRT-induced AR activity that can noninvasively be detected using [89Zr]11B6-PET; further clinical evaluation of hK2-PET for monitoring response and development of resistance to EBRT in real time is warranted.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response. · full record | OpenQuestion